Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bemosesuglimab
- Development stage
- Phase 2
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Bemosesuglimab (TQB2858) is a bifunctional fusion protein designed to simultaneously inhibit the programmed death-ligand 1 (PD-L1) and transforming growth factor-beta (TGF-β) signaling pathways. Developed by Jiangsu Chia Tai Tianqing Pharmaceutical Group, it consists of a humanized anti-PD-L1 IgG1 monoclonal antibody fused at the C-terminal of both heavy chains to the extracellular domain of the TGF-β receptor II (TGF-βRII). By targeting both pathways, bemosesuglimab aims to overcome primary and acquired resistance to PD-1/PD-L1 inhibitors, as TGF-β is a key mediator of immune exclusion and immunosuppression in the tumor microenvironment. It is primarily being investigated for the treatment of advanced solid tumors, including small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).
- Other names
- bemosesuglimab
02
Targets
TGFB3 (Transforming growth factor beta 3)TGFB1 (Transforming growth factor Beta-1 proprotein)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on bemosesuglimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bemosesuglimab.